Androgen deprivation therapy was associated with a 72 % higher risk of heart failure according to a study of patients with prostate cancerIn the  Journal of Clinical Pharmacology study, incidence rates of heart failure per 100 person-years within a 1-year follow-up period were 4.00 and 1.89 for androgen deprivation therapy users and nonusers, respectively

The study included data from the Taiwan Longitudinal Health Insurance Database 2005 on 1244 patient who received androgen deprivation therapy and 1806 patients who did not.

To eliminate potential bias, we performed a propensity score?matched cohort study. Each prostate cancer patient was tracked for 1 year from the index date to ascertain whether they were subsequently diagnosed with heart failure. 

Androgen deprivation therapy

In the full cohort study, incidence rates of heart failure per 100 person?years within the 1?year follow?up period were 4.00 (95%CI, 2.95?5.30) and 1.89 (95%CI, 1.30?2.66) for androgen deprivation therapy users and nonusers, respectively. In addition, the multivariable Cox regression indicated that the hazard ratio (HR) of heart failure among androgen deprivation therapy users was 1.72 (95%CI, 1.08?2.73) compared with those androgen deprivation therapy nonusers.

 In the propensity score?matched cohort study, the adjusted HR for heart failure among androgen deprivation therapy users was 1.92 (95%CI, 1.15?3.18) compared with propensity score?matched nonusers.

"The results of our study provide information for prostate cancer patients to be aware of the potential heart failure risk of receiving androgen deprivation therapy," the authors wrote. "We recommend that clinicians should counsel their patients regarding modifiable  heart failure  risk factors, suggest they improve their lifestyle, and further provide the relevant cardiovascular examination for prostate cancer patients receiving androgen deprivation therapy."